Tumor-related epilepsy and epilepsy surgery

Authors

  • Samden D. Lhatoo,

    Corresponding author
    1. Epilepsy Center, Neurological Institute, University Hospitals Case Medical Center, Cleveland, Ohio, U.S.A
    • Address correspondence to Samden D. Lhatoo, Epilepsy Center, Neurological Institute, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, U.S.A. E-mail: samden.lhatoo@uhhospitals.org

    Search for more papers by this author
  • Narges Moghimi,

    1. Epilepsy Center, Neurological Institute, University Hospitals Case Medical Center, Cleveland, Ohio, U.S.A
    Search for more papers by this author
  • Stephan Schuele

    1. Comprehensive Epilepsy Center, Department of Neurology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, Illinois, U.S.A
    Search for more papers by this author

Summary

Tumor-related epilepsy (TRE) is a major etiologic category of epilepsy. TRE is heterogeneous, and the epidemiology, pathology, pathophysiology, clinical features, treatment, and outcomes vary accordingly. In addition, treatment imperatives vary between almost purely epilepsy considerations and those that are primarily oncologic. Often, there is no clear separation of imperatives, and there is a relatively scant evidence base that underpins management decisions in such cases. Given a diverse molecular as well as clinical landscape and the rapid pace with which new knowledge accrues, there are relatively few recent literature resources on TRE that provide neurologists, neurosurgeons, epileptologists, and oncologists with an up-to-date, state-of-the-art review of the field in all of its important aspects. The proceedings of the Sixth International Epilepsy Colloquium in Cleveland in Ohio, U.S.A., in May 2013 on Tumoral Epilepsy and Epilepsy Surgery address, at least in part, several TRE aspects crucial to modern epilepsy and oncology practice.

Ancillary